GENE ONLINE|News &
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
Advances in genetics, pharmacology, and an improved understanding of molecular mechanisms have enabled the treatment of debilitating neurodegenerative diseases with high precision. Among the various cutting-edge treatment approaches, antisense oligonucleotides (ASOs) represent a promising approach by enabling reductions or modifications in RNA and protein expression.
Approved ASO therapies for Neurodegenerative and Neuromuscular Diseases
GO Prime with only $1.49 now
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
